Background: Biopsy is the usual gold standard for liver steatosis assessment. The aim of this study was to identify a panel of biomarkers (SteatoTest), with sufficient predictive values ...

−29% steatosis in −18% vs ... the clofibrate group showed no significant changes (not shown) in liver function and histology. #, fibrosis was assessed by FibroTest, not by pathology.

"The common pathological manifestation of MASLD is hepatic steatosis (fatty liver disease ... clinical studies on its effects in liver pathology. "Now we want to study its efficacy and safety ...